Lorazepam intranasal - Amarin

Drug Profile

Lorazepam intranasal - Amarin

Alternative Names: AMR-108; Nasal lorazepam

Latest Information Update: 26 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Corporation
  • Developer Amarin Corporation
  • Class Antiemetics; Anxiolytics; Benzodiazepinones; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Seizures; Status epilepticus

Most Recent Events

  • 25 Sep 2008 Lorazepam intranasal is available for licensing (http://www.amarincorp.com)
  • 14 Jan 2008 Amarin Corporation completes a preclinical, proof-of-concept trial in Seizures and Status epilepticus
  • 06 Mar 2007 Lorazepam intranasal licensed to Amarin Corporation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top